Format

Send to

Choose Destination
Therapie. 2016 Apr;71(2):179-86. doi: 10.1016/j.therap.2016.02.010. Epub 2016 Feb 6.

Causality assessment in pharmacovigilance: The French method and its successive updates.

[Article in English, French]

Author information

1
Service de pharmacologie médicale, centre de pharmacovigilance, CHU Pellegrin, 33076 Bordeaux, France; Inserm U657, département de pharmacologie médicale, université de Bordeaux, 33076 Bordeaux, France. Electronic address: ghada.miremont@u-bordeaux.fr.
2
Service de pharmacologie médicale, centre de pharmacovigilance, CHU Pellegrin, 33076 Bordeaux, France.
3
Service de pharmacologie médicale, centre de pharmacovigilance, CHU Pellegrin, 33076 Bordeaux, France; Inserm U657, département de pharmacologie médicale, université de Bordeaux, 33076 Bordeaux, France.
4
Inserm U657, département de pharmacologie médicale, université de Bordeaux, 33076 Bordeaux, France.

Abstract

The methods for causality assessment of adverse drug reactions were developed in the 1970s and 1980s, alongside the development of pharmacovigilance. The French method is one of the earlier of these, following on from the pioneering works by Irey and Karch and Lasagna. Initially published in 1978, it was updated in 1985, and again in 2011. The main alterations to the original method are presented in tables annexed to this paper. The successive versions improved the presentation, provided more formalised definitions of the criteria for assessing causality, while at the same time ensuring the method remained easy to use. Causality assessment enables the causal link between a drug and the occurrence of an adverse reaction to be formalised and explained. It contributes to diagnosis, and to determining the action to be taken in case of an adverse drug reaction. It can contribute to the quality and the relevance of the data stored in pharmacovigilance databases.

KEYWORDS:

Causality assessment; Drug-related side effects and adverse reactions; Imputability; Pharmacovigilance; Risk assessment/methods

PMID:
27080836
DOI:
10.1016/j.therap.2016.02.010
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center